TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03757325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNL747
Description: DNL747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT03070028

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: crystallised phenol
Description: crystallised phenol will be applied to sinus cavity
Study: NCT04683406

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir(oral)
Description: 2 X 75-mg tablet taken orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to ZSP1273
Description: Placebo capsules matching ZSP1273 600 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to ZSP1273
Description: Placebo capsules matching ZSP1273 600 mg
Study: NCT02523989

Intervention type: OTHER
Intervention: study group
Description: Explore the relationship of heavy metals and health related quality of life, including the relationship between the developmental delays and polymorphism of arsenic methylation enzymes, arsenic methylation capability and blood metals. Identify the interaction of children function, health condition, and quality of life and arsenic methylation and blood metals in children with developmental delays.

Intervention type: OTHER
Intervention: study group
Description: Explore the relationship of heavy metals and health related quality of life, including the relationship between the developmental delays and polymorphism of arsenic methylation enzymes, arsenic methylation capability and blood metals. Identify the interaction of children function, health condition, and quality of life and arsenic methylation and blood metals in children with developmental delays.
Study: NCT02170038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microgynon
Description: Subjects will receive 21 daily oral doses of Microgynon tablets containing 0.15 mg levonorgestrel und 0.03 mg ethinylestradiol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Noristerat(BAY86-6308)
Description: Subjects will receive one intramuscular dose of Noristerat (oily solution for intramuscular injection) containing 200 mg norethisterone enantate.
Study: NCT02877667

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: planar acoustic wave device
Description: accessory to laser treatment
Study: NCT03059004

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational SMS Messages
Description: The motivational SMS messages will be sent three times per week encouraging participants to complete their exercises.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational SMS Messages
Description: The motivational SMS messages will be sent three times per week encouraging participants to complete their exercises.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-Clinic Topical Therapy
Description: Subjects will be assigned to a physical therapist and will attend 14 in-clinic topical therapy sessions. Sessions will include application of ultrasound, gel, and manual therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-Clinic Exercise Therapy
Description: Subjects will be assigned to a physical therapist and will attend 14 in-clinic exercise and manual therapy sessions. Sessions will include the same exercises from the Home Exercise Program but the in-clinic therapy setting will allow for more personalization.
Study: NCT05000879

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MMB for Moms
Description: 12-week program that emphasizes mindfulness and cognitive behavioral skills
Study: NCT02513511

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laryngoscopy under hypnosis
Description: patient will be put in an hypnotic state before performing a laryngoscopy followed by oro-tracheal intubation
Study: NCT01206049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1,000 mg/m2 on day 1 of a 2 weeks cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1,000 mg/m2 on day 1 of a 2 weeks cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 60 mg/m2 on day 1 of a 2 weeks cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 60 mg/m2 on day 1 of a 2 weeks cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1,000 mg/m2 x 2 daily on days 1-7 of a 2 weeks cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1,000 mg/m2 x 2 daily on days 1-7 of a 2 weeks cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: 6 mg/kg on day 1 of a 2 weeks cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg on day 1 of a 2 weeks cycle
Study: NCT03514849

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prophylactic cranial irradiation (PCI)
Description: Patients in the control group are enrolled in the follow-up, and the patients in research group will receive prophylactic cranial irradiation （PCI） by 25 gy/10 fx.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: lobectomy + mediastinal lymph node dissection or systematic lymph node sampling
Description: lobectomy + mediastinal lymph node dissection or systematic lymph node sampling

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lobectomy + mediastinal lymph node dissection or systematic lymph node sampling
Description: lobectomy + mediastinal lymph node dissection or systematic lymph node sampling

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: postoperative adjuvant chemotherapy
Description: If the postoperatively pathological examination of the patient is confirmed to be in pT1-2N0 stage, a single postoperative adjuvant chemotherapy (combining etoposide with cisplatin) is recommended. If patients are difficult to tolerate the side effects of cisplatin, we can replace cisplatin by carboplatin in the adjuvant chemotherapy scheme.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: postoperative adjuvant chemotherapy
Description: If the postoperatively pathological examination of the patient is confirmed to be in pT1-2N0 stage, a single postoperative adjuvant chemotherapy (combining etoposide with cisplatin) is recommended. If patients are difficult to tolerate the side effects of cisplatin, we can replace cisplatin by carboplatin in the adjuvant chemotherapy scheme.
Study: NCT00258050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Subjects will receive midazolam by oral or IV route on Days 1, 3, 9 and 11. Oral midazolam was supplied as 3 mg tablets; IV midazolam was supplied as 1 milligram per milliliter (mg/L) sterile solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Subjects will receive 1500 mg lapatinib by oral route once daily from Day 4.
Study: NCT02894281

Intervention type: DEVICE
Intervention: pupillary light reflex
Description: measure with infra-red cameras

Intervention type: DEVICE
Intervention: pupillary light reflex
Description: measure with infra-red cameras
Study: NCT02968836

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Blend of amino acids
Description: The product was poured in bottles containing the enteral nutrition that the patient received as standard of care.
Study: NCT04660175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non-resistance therapy
Description: The non-resistance technique, created in Jaseng Hospital, is a combination of ischemic compression and mobilization It is a treatment that improves the limited range of motion of the cervical spine and relieves pain by applying ischemic pressure to the induration of the neck and at the same time firmly supporting the patient's head to give passive joint movements and completely relax.
Study: NCT04420910

Intervention type: OTHER
Intervention: Non-Motor Symptoms
Description: NMSs of the participants were evaluated using the Non-Motor Symptoms Scale (NMSS). The scale consists of 30 yes-no questions and is administered face to face with the therapist.
Study: NCT04660175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: According to the judgment of the oriental medicine doctor, select acupuncture point and tender spots such as BL10, TE14, GB20, GV16, etc. to a depth of 10 mm 6 -Self needle in 12 blood spots.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: According to the judgment of the oriental medicine doctor, select acupuncture point and tender spots such as BL10, TE14, GB20, GV16, etc. to a depth of 10 mm 6 -Self needle in 12 blood spots.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chuna
Description: Chuna treatment is administered once a day during the hospitalization period. Chuna is Korean manual therapy using methods such as joint mobilization, joint distraction, fascia relaxation and manipulation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chuna
Description: Chuna treatment is administered once a day during the hospitalization period. Chuna is Korean manual therapy using methods such as joint mobilization, joint distraction, fascia relaxation and manipulation.
Study: NCT02968836

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin only
Description: The product was poured in bottles containing the enteral nutrition that the patient received as standard of care.
Study: NCT04660175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacoacupuncture
Description: This is an oriental medical practice in which a certain amount of a drug extracted from a specific herbal medicine is injected with an injector to treat the patient's constitution, disease state, etc., and then injected into the treatment acupuncture points and body surface reaction points. Depending on the condition of the inpatient, acupuncture is used in parallel.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacoacupuncture
Description: This is an oriental medical practice in which a certain amount of a drug extracted from a specific herbal medicine is injected with an injector to treat the patient's constitution, disease state, etc., and then injected into the treatment acupuncture points and body surface reaction points. Depending on the condition of the inpatient, acupuncture is used in parallel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Korean herbal medicine
Description: Formulated with herbal medicinal and pack the extract in a pouch, and have the hospitalized patient take it once in the morning and afternoon for 30 minutes after meals.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Korean herbal medicine
Description: Formulated with herbal medicinal and pack the extract in a pouch, and have the hospitalized patient take it once in the morning and afternoon for 30 minutes after meals.
Study: NCT03234647

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Doraya catheter
Description: Temporary deployment of the Doraya catheter in AHF patients.
Study: NCT03292003

Intervention type: DEVICE
Intervention: Journey II BCS Total Knee System
Study: NCT02887157

Intervention type: DEVICE
Intervention: Swept Source OCT
Description: The swept source optical coherence tomography device was developed at Duke University as the result of collaboration between the Departments of Ophthalmology and Biomedical Engineering. The SSOCT system has a 100kHz repetition rate, 1050nm-centered swept-source light source (Axsun Technologies). This swept-source system allows near real-time OCT imaging during movement while imaging and it provides better OCT imaging of the choroid. The SSOCT system is a non-contact device and therefore does not touch the eye.

Intervention type: DEVICE
Intervention: Swept Source OCT
Description: The swept source optical coherence tomography device was developed at Duke University as the result of collaboration between the Departments of Ophthalmology and Biomedical Engineering. The SSOCT system has a 100kHz repetition rate, 1050nm-centered swept-source light source (Axsun Technologies). This swept-source system allows near real-time OCT imaging during movement while imaging and it provides better OCT imaging of the choroid. The SSOCT system is a non-contact device and therefore does not touch the eye.
Study: NCT02634450

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alere q
Study: NCT02467166

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Circa™ Probe
Description: The Circa™ probe will be used to monitor esophageal temperature and guide ablation power and duration during the RFCA procedure. Following ablation esophagoscopy will be performed to assess for esophageal lesions.
Study: NCT04218266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2433334
Description: Tablet, taken orally once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2433334
Description: Tablet, taken orally once a day.
Study: NCT04420910

Intervention type: OTHER
Intervention: Functional mobility
Description: The Timed Up and Go test (TUG) was used in the evaluation of functional mobility. . For this test, participants were seated on a standard armless chair and a cone was placed 3 meters away from the chair. Participants were instructed to stand up and (1) walk towards the cone, (2) turn around the cone, (3) walk back to the chair, and (4) sit back on the chair. It was stated that patients should walk without running but as fast as possible. Dual task performance was performed by adding cognitive and motor tasks into the TUG.
Study: NCT03337425

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational group therapy
Description: The group-based psychoeducational program consists of 10 sessions, run over 10 consecutive weeks. Each session consist of a lecture, given by a recruited expert on the topic of the session (20 minutes) with a following discussion of the topic (45 minutes), facilitated by the course leader. All sessions are organized and led by the course leader, which also includes keeping structure in time, discussion and closing of the session. Psychoeducation comes in addition to standard treatment (ADHD treatment as usual).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waiting list
Description: Waiting list and standard treatment (ADHD treatment as usual)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Standard treatment consists of diagnostic assessment of ADHD and comorbidity, as well as treatment with medication. In addition, some patients receive cognitive behavioral therapy, although this is not systematically given to every patient. If needed, patients are also offered assistance with regard to economy, housing, education and work. As well as contact with family and network.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: Standard treatment consists of diagnostic assessment of ADHD and comorbidity, as well as treatment with medication. In addition, some patients receive cognitive behavioral therapy, although this is not systematically given to every patient. If needed, patients are also offered assistance with regard to economy, housing, education and work. As well as contact with family and network.
Study: NCT02204033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc - labelled hMAb BIWA 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc - labelled hMAb BIWA 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc - labelled hMAb BIWA 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 186 Re - labelled hMAb BIWA 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: unlabelled hMAb BIWA 4 - low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: unlabelled hMAb BIWA 4 - medium dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: unlabelled hMAb BIWA 4 - high dose
Study: NCT03689881

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tomosynthesis of SI joints
Description: All patients will undergo additional tomosynthesis performed per study protocol along with Xray and CT performed as part of standard imaging evaluation of sacroillitis.~Tomosynthesis of SI joints will be performed on a digital Tomosynthesis system (PLATINUM dRF v2 DMS/APELEM), with a single acquisition followed by coronal image reconstruction.
Study: NCT02758613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study: NCT04454580

Intervention type: DRUG
Intervention: Venetoclax
Description: treatment with azacitidine or decitabine in combination with venetoclax
Study: NCT03310580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-13324 Ophthalmic Solution 0.02%
Description: Administered to each eye, once daily (QD) in the evening (PM) for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-13324 Ophthalmic Solution 0.04%
Description: Administered to each eye, once daily (QD) in the evening (PM) for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AR-13324 Ophthalmic Solution Placebo
Description: Administered to each eye, once daily (QD) in the evening (PM) for 28 days
Study: NCT01548794

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spinal anesthesia
Description: To receive 2 ml heavy bupivacaine + 0,6 ml saline

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinal anesthesia
Description: To receive 2ml bupivacaine +0,6 ml 1% lidocaine for spinal anesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: infiltration anesthesia
Description: To receive step by step local infiltration anesthesia as described by the Lichtenstein Institute.
Study: NCT04991064

Intervention type: OTHER
Group type: OTHER
Intervention: Complete denture base modified by Titanium dioxide nanoparticles.
Description: Titanium dioxide nanoparticles will be mixed with resin powder of the denture base before mixing the powder and liquid of the heat cure denture base material.
Study: NCT04218266

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Capsule, taken orally twice a day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BAY2433334 matching placebo
Description: Tablet, taken orally once a day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apixaban matching placebo
Description: Capsule, taken orally twice a day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apixaban matching placebo
Description: Capsule, taken orally twice a day.
Study: NCT01577225

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPSITE POST-OP VISIBLE
Description: Patient will be treated with OPSITE POST-OP VISIBLE dressing up to 14 days post surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tape and Gauze
Description: Patient will be treated with tape and gauze up to 14 days post surgery
Study: NCT03628235

Intervention type: BEHAVIORAL
Intervention: Online survey
Description: Online survey to capture indirect and out of pocket costs of Huntington's Disease in HDGECs and companions

Intervention type: BEHAVIORAL
Intervention: Online survey
Description: Online survey to capture indirect and out of pocket costs of Huntington's Disease in HDGECs and companions

Intervention type: BEHAVIORAL
Intervention: Online survey
Description: Online survey to capture indirect and out of pocket costs of Huntington's Disease in HDGECs and companions

Intervention type: BEHAVIORAL
Intervention: Online survey
Description: Online survey to capture indirect and out of pocket costs of Huntington's Disease in HDGECs and companions

Intervention type: BEHAVIORAL
Intervention: Online survey
Description: Online survey to capture indirect and out of pocket costs of Huntington's Disease in HDGECs and companions

Intervention type: BEHAVIORAL
Intervention: Online survey
Description: Online survey to capture indirect and out of pocket costs of Huntington's Disease in HDGECs and companions
Study: NCT03435666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Single oral dose (1250mg/m2) Capecitabine or XELODA in each period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Single oral dose (1250mg/m2) Capecitabine or XELODA in each period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELODA
Description: Single oral dose (1250mg/m2) Capecitabine or XELODA in each period.
Study: NCT00927719

Intervention type: BIOLOGICAL
Intervention: ACAM2000® smallpox vaccine
Description: Previous vaccination, no vaccine is administered in this study.
Study: NCT01854671

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: family planning counseling let by community health workers
Description: The family planning counseling sessions led by community health workers will present advantages of birth spacing, available methods of postpartum contraception, contraindications (if any) for the method, when each method can be safely started postpartum, where each method can be obtained, and importance of 6 week postpartum clinic follow-up. There will also be a take-home contraceptive method brochure given at conclusion of information session -primarily pictorial and in Arabic, to facilitate discussion at home with husbands and family members.
Study: NCT04203875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orencia® (Abatacept)
Description: Orencia® (Abatacept) will be administered once a week for 6 months subcutaneously (injection under the skin) with an option to continue to receive Abatacept weekly injections for an additional 6 months, for a total of 12 months if there is a positive response.
Study: NCT01557738

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Flavanol Trial
Description: The experimental trial (high flavanol content) will involve the consumption of a beverage containing about 1000mg of cocoa flavanols.
Study: NCT01303458

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic Needs Surveillance (BNS) protocol
Description: The BNS intervention will consist of 4 components: 1) WE CARE survey which mothers will fill out in the waiting room prior to their child's WCC visits; 2) Family Resource book containing 1-page information sheets on resources, that providers will have access to in exam rooms; 3) a Community Resource Coordinator who will assist families link to available resources, and update providers; 4) Training Session which will provide a 1 hr overview of the intervention to providers
Study: NCT02640118

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lixisenatide
Description: single injection of 20 µg lixisenatide subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lixisenatide
Description: single injection of 20 µg lixisenatide subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lixisenatide-Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lixisenatide-Placebo